- Home
- CCCC vs BIOA Comparison
CCCC vs BIOA Comparison
Compare CCCC & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- BIOA
- Stock Information
- Founded
- CCCC 2015
- BIOA 2015
- Country
- CCCC United States
- BIOA United States
- Employees
- CCCC N/A
- BIOA N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- CCCC Health Care
- BIOA Health Care
- Exchange
- CCCC Nasdaq
- BIOA Nasdaq
- Market Cap
- CCCC 175.1M
- BIOA 175.7M
- IPO Year
- CCCC 2020
- BIOA 2024
- Fundamental
- Price
- CCCC $2.23
- BIOA $5.45
- Analyst Decision
- CCCC Strong Buy
- BIOA Hold
- Analyst Count
- CCCC 4
- BIOA 4
- Target Price
- CCCC $8.50
- BIOA $5.67
- AVG Volume (30 Days)
- CCCC 1.8M
- BIOA 189.4K
- Earning Date
- CCCC 10-30-2025
- BIOA 11-06-2025
- Dividend Yield
- CCCC N/A
- BIOA N/A
- EPS Growth
- CCCC N/A
- BIOA N/A
- EPS
- CCCC N/A
- BIOA N/A
- Revenue
- CCCC $34,240,000.00
- BIOA $3,863,000.00
- Revenue This Year
- CCCC N/A
- BIOA N/A
- Revenue Next Year
- CCCC N/A
- BIOA N/A
- P/E Ratio
- CCCC N/A
- BIOA N/A
- Revenue Growth
- CCCC 16.55
- BIOA N/A
- 52 Week Low
- CCCC $1.09
- BIOA $2.88
- 52 Week High
- CCCC $7.14
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- CCCC 38.70
- BIOA 63.40
- Support Level
- CCCC $2.13
- BIOA $4.88
- Resistance Level
- CCCC $3.43
- BIOA $5.34
- Average True Range (ATR)
- CCCC 0.30
- BIOA 0.26
- MACD
- CCCC -0.12
- BIOA 0.04
- Stochastic Oscillator
- CCCC 6.58
- BIOA 95.06
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.